The Technology Development Board (TDB) under the Department of Science and Technology has signed an agreement with Odisha-based Prantae Solutions Private Limited to provide financial assistance for the manufacturing and commercialisation of an indigenous point-of-care renal diagnostic platform, Proflo-U.
The project aligns with the government’s Aatmanirbhar Bharat vision and aims to strengthen affordable, technology-driven primary healthcare systems by enabling early detection and monitoring of kidney disease and pregnancy-related complications.
Chronic Kidney Disease (CKD) remains a significant public health concern in India, with more than two lakh new patients estimated to progress annually to end-stage renal disease. Early diagnosis through biomarkers such as urine albumin, creatinine and the Albumin-to-Creatinine Ratio (ACR) is critical, particularly among high-risk groups including individuals with diabetes, hypertension and the elderly population. These biomarkers are also essential for identifying pregnancy-related complications such as preeclampsia and form part of the Indian Council of Medical Research’s essential diagnostics for antenatal care.
Despite their importance, reliable quantitative testing solutions at the primary healthcare level remain limited. Gold-standard immunoturbidometric methods are largely restricted to laboratories, while conventional dipstick tests often lack sensitivity for early-stage detection.
Proflo-U has been developed to address this gap through a patented, indigenous platform comprising urine albumin and urine creatinine measurement kits along with a portable urine analyser. The nano-sensor based urine albumin kit and the creatinine testing device offer wide detection ranges and stability at room temperature, making them suitable for field settings. The lightweight, rechargeable analyser integrates absorbance and fluorescence technologies and is Bluetooth and IoT enabled. It connects to a mobile application equipped with AI and machine learning features and supports calibration-free functionality.
The initiative includes the establishment of a manufacturing and commercialisation facility in Odisha to scale up production and expand access across primary health centres, diagnostic networks and antenatal care systems. The platform has been clinically validated against established laboratory standards and is designed to deliver laboratory-grade accuracy in point-of-care environments.
Through this partnership, TDB aims to strengthen indigenous diagnostic innovation and improve last-mile access to early screening tools, with the broader goal of reducing disease burden and healthcare costs through timely detection and intervention.
